Drug Profile
Research programme: macrocyclic peptide therapeutics - Merck/PeptiDream
Alternative Names: Macrocyclic peptide - PeptiDreamLatest Information Update: 28 Dec 2021
Price :
$50
*
At a glance
- Originator Merck & Co; PeptiDream
- Class Antivirals; Macrocyclic compounds; Peptides
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research COVID 2019 infections
- No development reported Unspecified
Most Recent Events
- 28 Dec 2021 No recent reports of development identified for research development in Unspecified in Japan
- 28 Dec 2021 No recent reports of development identified for research development in Unspecified in USA
- 12 Jun 2020 Merck and PeptiDream agree to collaborate for the discovery and development of peptide therapeutics for COVID-19 infections